PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay

Yasunari Sakamoto, Seri Yamagishi, Yoshinori Tanizawa, Masaomi Tajimi, Takuji Okusaka, Hidenori Ojima

Research output: Contribution to journalArticle

2 Citations (Scopus)


Biliary tract carcinoma (BTC) is an extremely malignant tumor, but available treatment options are limited. Despite of needs for novel therapies, few BTC-related resources are currently available for evaluation of candidate drugs. To address this issue, we have recently established 13 cell lines from surgical specimens from Japanese BTC patients. In the present study, we evaluated four new molecular targeting agents using our BTC cell-based assay panel with 17 BTC cell lines. PI3K/ mTOR dual inhibitor LY3023414 showed activity at submicromolar concentration ranges against 13 of the 17 cell lines tested, including the ones with gemcitabine insensitivity. In conclusion, we demonstrated that in vitro study with the BTC cell line panel would be an efficient approach to screen for novel therapeutic strategies. Although this is preliminary result and further investigations are required for confirmation, PI3K/mTOR inhibitor might be a potential target for BTC drug development.

Original languageEnglish
Pages (from-to)396-399
Number of pages4
JournalJapanese Journal of Clinical Oncology
Issue number4
Publication statusPublished - 2018 Apr 1



  • Antitumor
  • Biliary tract cancer
  • Drug resistance
  • Drug screening assays
  • Neoplasm
  • Phosphatidylinositol 3-kinases
  • Serine-threonine kinases
  • TOR

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this